Exelixis: A Strong Contender in the Cancer Drug Market

Exelixis, a cancer drug developer, is discussed in a Motley Fool Scoreboard episode. The company's stock is analyzed by contributing expert analysts, and the video provides insights into market trends and potential investment opportunities. Exelixis is a strong contender in the cancer drug market, and investors are encouraged to consider the company's prospects before making a decision.